Graft

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to register today!
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blume, C.
Right arrow Articles by Grabensee, B.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Graft, Vol. 5, No. 3, 128-131 (2002)
DOI: 10.1177/1522162802005003002
© 2002 SAGE Publications

Successful Conversion of Immunosuppressives from Cyclosporine to Tacrolimus in Chronic Rejection after Kidney Transplantation

Cornelia Blume

Markus Hollenbeck

Katrin Ivens

Peter Heering

Gerd-Rüdiger Hetzel

Bernd Grabensee

The persistence of chronic renal allograft nephropathy is an important cause of graftloss. Here the authors describe the 1st long-term results after switching from cyclosporinA (CyA) to tacrolimus in patients with chronic allograft nephropathy. Eighteenpatients had chronic allograft nephropathy confirmed by biopsy. Mean observation periodwas 12.3 months. The mean rate of decline in glomerular filtration (1/serum creatinine x?100/year) was measured as a function of time before and after conversion therapyusing linear regression analysis. The regression coefficients were compared usingthe Student t-test for paired samples. Conversion to tacrolimus significantly reduced theprogression to kidney failure. Kidney function was stable in the observed time intervalas the mean change of glomerular filtration rate decelerated significantly (1/creatinineper year x 100, P< 0.029). Lipids and blood pressure values were significantly loweredafter conversion therapy. The authors' results suggest that switching from CyA totacrolimus is adequate for treating chronic rejection in kidney allograft recipients.

Key Words: acute and chronic kidney allograft refection • hypertension • conversion treatment • serum lipids • Tacrolimus (FK 506) • blood pressure


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?